Q2 2024 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2024-08-14 · accession 0000899140-24-000887
$592.4M
Reported value
10
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 09062X103 | BIIB | BIOGEN INC | $149.1M | 25.2% | 643,000 | Common | SOLE |
| 45781M101 | INVA | INNOVIVA INC | $119.3M | 20.1% | 7,277,000 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $106.9M | 18.0% | 16,390,000 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $75.7M | 12.8% | 1,103,282 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $60.1M | 10.2% | 1,110,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $56.5M | 9.54% | 410,483 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $17.1M | 2.89% | 24,850,623 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $6.8M | 1.14% | 1,094,168 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $618,000 | 0.10% | 618,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $330,552 | 0.06% | 185,183 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.